Article in Dagens Industri Invest Talks, March 2021
With its powerful and versatile platform, Beactica Therapeutics identifies innovative small molecule drug candidates that have a targeted effect against carefully selected disease proteins. Strategic collaborations provide access to valuable knowledge and opportunities to work with a broader portfolio. We speak to the company's CEO, Dr Per Källblad.
Read the full original Swedish article here, and the translation in English here.
Sign up for the Beactica newsletter to receive our latest news and updates